Evotec SE to announce results for fiscal year 2020 on 25 March 2021

Rhea-AI Summary

Evotec SE plans to announce its 2020 financial results on March 25, 2021. A conference call will follow to discuss these results and provide performance updates. The call will be conducted in English at 02:00 pm CET. Interested participants can access the call via various international phone numbers or join the audio webcast available on the company's homepage. Evotec operates actively in drug discovery and development, boasting over 100 co-owned product opportunities across various therapeutic areas, as per their strategic partnerships with leading pharmaceutical companies.

Positive

• Evotec has established over 100 co-owned product opportunities at clinical, pre-clinical, and discovery stages.
• The company maintains long-term alliances with prominent partners including Bayer, Novartis, and Pfizer.

Negative

• None.

HAMBURG, GERMANY / ACCESSWIRE / March 18, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for 2020 on Thursday, 25 March 2021.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Conference call details
Date: Thursday, 25 March 2021
Time: 02.00 pm CET (09.00 am EDT, 01.00 pm GMT)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From UK: +44 20 3009 2470
From USA: +1 877 423 0830
Access Code: 54325009#

A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20210325/no-audio.

Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362. The access code is 315614520#

The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG

View source version on accesswire.com:
https://www.accesswire.com/636262/Evotec-SE-to-announce-results-for-fiscal-year-2020-on-25-March-2021

FAQ

When will Evotec announce its 2020 financial results?

Evotec will announce its 2020 financial results on March 25, 2021.

What time is the Evotec conference call scheduled?

The Evotec conference call is scheduled for 02:00 pm CET on March 25, 2021.

How can I access the Evotec financial results conference call?

You can access the Evotec conference call via various international phone numbers or join the audio webcast available on their homepage.

What are the strategic areas Evotec focuses on?

Evotec focuses on drug discovery and development across various therapeutic areas including oncology, infectious diseases, and neuronal diseases.